B Zhang1, D Li, Q Shi, X L Ju. 1. Department of Pediatrics, Qilu Hospital, Shandong University, Jinan 250012, China.
Abstract
Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells. Methods: Low O-GlcNAc modified Nalm-6 cells model was established with Alloxan, an inhibitor of OGT. The influence of Alloxan on Nalm-6 cells proliferation was checked by CCK-8 assay, apoptosis and cell cycle by flow cytometry. Nalm-6 cells were treated with different concentrations of Vp16 for 12 h, and then the O-GlcNAc level and the expressions of OGT were examined by Western blot. After treating Nalm-6 with Alloxan for 24 h and then 5 μg/ml of Vp16 for 12 h, the apoptosis of different groups were measured with flow cytometry, and the expression of apoptosis-associated proteins Bax and Bcl-2 were examined by Western blot. Results: With the concentration of Vp16 increasing, the O-GlcNAc modified levels of total protein and the expression of OGT were up regulated (P<0.05, n=6) ; Alloxan could slow down the proliferation capacity, induce apoptosis[ (15.190±2.539) % vs (21.910±4.105) %, P=0.007], arrest cell cycle[G1 phase: (43.534±4.453) % vs (57.322±6.091) %, P=0.003; S phase: (50.747±5.937) % vs (37.201±4.661) %, P=0.001]. Alloxan could inhibit the apoptosis caused by Vp16[ (75.195±13.845) % vs (52.741±10.815) %, P=0.011]along with Bax decreasing (5.496±1.998 vs 2.950±0.703, P=0.015) and Bcl-2 increasing (0.454±0.125 vs 0.803±0.223, P=0.013) . Conclusion: Changes of O-GlcNAc modified level of Nalm-6 cells along with the inhibition of OGT could influence the biological behaviors and inhibit apoptosis induced by Vp16.
Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells. Methods: Low O-GlcNAc modified Nalm-6 cells model was established with Alloxan, an inhibitor of OGT. The influence of Alloxan on Nalm-6 cells proliferation was checked by CCK-8 assay, apoptosis and cell cycle by flow cytometry. Nalm-6 cells were treated with different concentrations of Vp16 for 12 h, and then the O-GlcNAc level and the expressions of OGT were examined by Western blot. After treating Nalm-6 with Alloxan for 24 h and then 5 μg/ml of Vp16 for 12 h, the apoptosis of different groups were measured with flow cytometry, and the expression of apoptosis-associated proteins Bax and Bcl-2 were examined by Western blot. Results: With the concentration of Vp16 increasing, the O-GlcNAc modified levels of total protein and the expression of OGT were up regulated (P<0.05, n=6) ; Alloxan could slow down the proliferation capacity, induce apoptosis[ (15.190±2.539) % vs (21.910±4.105) %, P=0.007], arrest cell cycle[G1 phase: (43.534±4.453) % vs (57.322±6.091) %, P=0.003; S phase: (50.747±5.937) % vs (37.201±4.661) %, P=0.001]. Alloxan could inhibit the apoptosis caused by Vp16[ (75.195±13.845) % vs (52.741±10.815) %, P=0.011]along with Bax decreasing (5.496±1.998 vs 2.950±0.703, P=0.015) and Bcl-2 increasing (0.454±0.125 vs 0.803±0.223, P=0.013) . Conclusion: Changes of O-GlcNAc modified level of Nalm-6 cells along with the inhibition of OGT could influence the biological behaviors and inhibit apoptosis induced by Vp16.
1. Western blot检测Alloxan对Nalm-6细胞OGT表达及O-GlcNAc糖基化水平的影响:以不同浓度的Alloxan处理细胞24 h后,Nalm-6细胞OGT表达以及O-GlcNAc糖基化程度逐渐降低(P<0.05),并且有一定的剂量依赖性。Alloxan浓度为10 mmol/L时,O-GlcNAc降低最为明显,可以此浓度构建低O-GlcNAc细胞模型。详见图1。
图1
Western blot检测不同浓度四氧嘧啶(Alloxan)对Nalm-6细胞乙酰氨基葡萄糖转移酶(OGT)表达和O-GlcNAc糖基化的影响(P<0.05,n=6)
2. Western blot检测Vp16对Nalm-6细胞OGT表达及O-GlcNAc糖基化水平的影响:随着Vp16浓度的增加,Nalm-6细胞内OGT表达量逐渐增加。在低浓度Vp16组,细胞总蛋白O-GlcNAc糖基化程度变化不明显,当Vp16浓度达到1 µg/ml时,O-GlcNAc糖基化程度明显增高(P<0.05,n=6)。详见图2。
Authors: T Kamigaito; T Okaneya; M Kawakubo; H Shimojo; O Nishizawa; J Nakayama Journal: Prostate Cancer Prostatic Dis Date: 2013-12-24 Impact factor: 5.554
Authors: Robert J Konrad; Fengxue Zhang; John E Hale; Michael D Knierman; Gerald W Becker; Jeffrey E Kudlow Journal: Biochem Biophys Res Commun Date: 2002-04-26 Impact factor: 3.575
Authors: S Olivier-Van Stichelen; L Drougat; V Dehennaut; I El Yazidi-Belkoura; C Guinez; A-M Mir; J-C Michalski; A-S Vercoutter-Edouart; T Lefebvre Journal: Oncogenesis Date: 2012-12-10 Impact factor: 7.485
Authors: Harri M Itkonen; Saurabh S Gorad; Damien Y Duveau; Sara E S Martin; Anna Barkovskaya; Tone F Bathen; Siver A Moestue; Ian G Mills Journal: Oncotarget Date: 2016-03-15